The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flaño, E.
Right arrow Articles by Blackman, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flaño, E.
Right arrow Articles by Blackman, M. A.
The Journal of Immunology, 2005, 174: 4972-4978.
Copyright © 2005 by The American Association of Immunologists

Early Establishment of {gamma}-Herpesvirus Latency: Implications for Immune Control1

Emilio Flaño2,*, Qingmei Jia{dagger}, John Moore*, David L. Woodland*, Ren Sun{dagger} and Marcia A. Blackman3,*

* Trudeau Institute, Saranac Lake, NY 12983; and {dagger} Department of Molecular and Medical Pharmacology, AIDS Institute, Jonsson Comprehensive Cancer Center, Dental Research Institute, and Molecular Biology Institute, University of California, Los Angeles, CA 90095


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The human {gamma}-herpesviruses, EBV and Kaposi’s sarcoma-associated herpesvirus, infect >90% of the population worldwide, and latent infection is associated with numerous malignancies. Rational vaccination and therapeutic strategies require an understanding of virus-host interactions during the initial asymptomatic infection. Primary EBV infection is associated with virus replication at epithelial sites and entry into the circulating B lymphocyte pool. The virus exploits the life cycle of the B cell and latency is maintained long term in resting memory B cells. In this study, using a murine {gamma}-herpesvirus model, we demonstrate an early dominance of latent virus at the site of infection, with lung B cells harboring virus almost immediately after infection. These data reinforce the central role of the B cell not only in the later phase of infection, but early in the initial infection. Early inhibition of lytic replication does not impact the progression of the latent infection, and latency is established in lymphoid tissues following infection with a replication-deficient mutant virus. These data demonstrate that lytic viral replication is not a requirement for {gamma}-herpesvirus latency in vivo and suggest that viral latency can be disseminated by cellular proliferation. These observations emphasize that prophylactic vaccination strategies must target latent {gamma}-herpesvirus at the site of infection.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The oncogenic human {gamma}-herpesviruses, EBV and Kaposi’s sarcoma-associated herpesvirus (KSHV),4 persist in the host because of their ability to establish and maintain latent infection using a complex strategy of immune evasion and immune exploitation. Because of their prevalence in the population and association with a wide variety of malignancies, including Burkitt’s lymphoma, Hodgkin’s disease, nasopharyngeal carcinoma, and Kaposi’s sarcoma, prophylactic vaccines to prevent the establishment of {gamma}-herpesvirus latency are eagerly sought. To design rational vaccine strategies, it is important to understand virus-host interactions during the initial infection. However, events associated with primary human {gamma}-herpesvirus infections are not well characterized because of the asymptomatic nature of the initial infection. The murine {gamma}-herpesvirus, MHV-68 or {gamma}HV68, is a {gamma}-herpesvirus closely related to EBV and KSHV (1, 2) and provides an important in vivo experimental model for elucidating fundamental principals of {gamma}-herpesvirus infection, immune mechanisms of control, and vaccination strategies.

The {gamma}-herpesviruses are B lymphotrophic viruses that establish and maintain latent infection exploiting the host B lymphocyte life cycle (3, 4, 5, 6, 7, 8). Analysis of the early events in EBV infection has been limited to in vitro studies or characterization of the infectious mononucleosis response, which is manifest well after viral colonization of B lymphocytes. According to the classic model, virus infection and proliferation in oropharyngeal epithelial cells leads to secondary latent infection of B lymphocytes (9). However, other models favor the B lymphocyte playing a central role in both primary and persistent infection (4, 10, 11). The current study exploits the mouse model to characterize the early stages of {gamma}HV68 infection of B lymphocytes. Following intranasal administration of low doses of virus to mice, {gamma}HV68 induces an acute respiratory infection, which is cleared, followed by the establishment of lifelong latency (12). We demonstrate, first, that {gamma}HV68 localizes in B lymphocytes as early as day 1 after infection and that latently infected cells constitute a large component of the viral reservoir in the lung during the acute infection. Second, we show that early inhibition of viral replication has no major kinetic or quantitative effect on the establishment of splenic latency. Third, using a replication-deficient virus, {gamma}HV68 ORF31STOP (13), we also demonstrate that {gamma}-herpesviruses do not require viral replication for the establishment of latency in lymphoid organs after i.p., but not intranasal, infection. Altogether, the data indicate that B cells play a central role in the initial viral infection and that establishment of latency occurs early after infection and is not dependent on lytic viral replication. Furthermore, the data suggest that the dissemination of latency can be mediated by cellular proliferation. These insights into early events in the establishment and dissemination of latency have important implications for therapeutic and vaccination strategies against {gamma}-herpesviruses.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Animal procedures and virus infection

{gamma}HV68, clone WUMS, was propagated and titered on monolayers of NIH-3T3 fibroblasts. A replication-deficient transgenic virus, {gamma}HV68 ORF31STOP, was generated using the {gamma}HV68 BAC system (13). C57BL/6J mice were purchased from Taconic Farms and housed under specific pathogen-free conditions in BL3 containment. The Institutional Animal Care and Use Committee at the Trudeau Institute approved all studies described here. Mice were anesthetized with 2,2,2-tribromoethanol and inoculated with 4 x 102–7.5 x 105 PFU of virus in PBS. To prevent viral replication, mice were i.p. inoculated daily beginning on day 3 following infection with 125 µg of cidofovir (kindly supplied by Gilead Sciences) diluted in PBS, which effectively inhibits lytic {gamma}HV68 replication in vivo (Refs. 14 and 15 ; our unpublished data).

Viral assays

Plaque assay. To determine the titer of infectious virus, lungs obtained at various times after infection were stored frozen and mechanically homogenized. The cells were broken by three quick successive cycles of freeze-thawing. The lytic virus concentration of the lung homogenates was determined in a standard plaque assay on NIH-3T3 fibroblasts. The next day the monolayers were overlaid with carboxymethyl cellulose (Sigma-Aldrich). After 6 days of culture, plaques were quantitated after methanol fixation and Giemsa staining

Limiting dilution-nested PCR. The number of cells containing the {gamma}HV68 genome was determined by a combination of limiting dilution analysis and nested PCR (16). To isolate lung cells, mice were perfused with 50 ml of PBS and the lungs were treated with 5 mg/ml collagenase D (Roche) and 5 mM PBS/EDTA as described elsewhere (16). The total number of cells isolated per organ was determined and the cells were serially diluted in uninfected NIH-3T3 fibroblasts in 96-well plates, lysed, and DNA amplified by nested PCR as described previously (16, 17) using primers specific for {gamma}HV68 ORF50. This procedure was able to consistently detect a single copy of the target sequence. Twelve replicates were assessed for each cell dilution, and linear regression analysis was performed to determine the reciprocal frequency (95% degree of confidence) of cells positive for {gamma}HV68 DNA. As controls of nested PCR, 104 NIH-3T3 cells/well with and without plasmid DNA containing the {gamma}HV68 ORF50 gene were included in each 96-well plate.

Infectious center assay. To determine the number of latently and lytically {gamma}HV68-infected cells, we used a modification of the infective center assay as previously described (16). Single-cell suspensions from spleen and lung were obtained as described above. Duplicates of the cell sample were mechanically disrupted using a Minibeadbeater 3110BX (Biospec Products) in the presence of 0.5-mm zirconia/silica beads. This procedure involves cell membrane cracking rather than high shear (manufacturer specifications). The complete killing of the cells (>98%) without destruction of the cellular integrity was confirmed by propidium iodine staining and flow cytometry analysis. The intact (total infected cells) and disrupted (lytically infected cells) cell samples from each organ were plated in triplicate onto monolayers of NIH-3T3 cells in serial 10-fold dilutions in 12-well plates. The monolayers were overlaid and the plaques were quantitated as described above. The number of latently infected cells was calculated as the difference between total and lytically infected cells.

In vivo infections are nonsynchronous, and thus any cell committed to viral replication that has not yet produced infectious viral particles will score as latently infected in an infectious center assay. Therefore, a conventional infectious center assay underestimates the frequency of lytically infected cells. To overcome this limitation of the assay, we have designed a modified infectious center assay to determine the relative contribution of cells committed to the lytic cycle and of true latently infected cells to the total pool of infected cells. A single-cell suspension from lung obtained as described above was maintained at 37°C under continuous rotation in tissue culture medium to allow lytically infected cells to complete their lytic replication cycle in vitro. Cells were sampled at different intervals (0, 8, and 12 h), washed to eliminate viral particles in the supernatant, counted, and a duplicate of the samples was mechanically disrupted as described above. The intact (total infected cells) and disrupted (lytically infected cells) cell samples were plated in triplicate onto permissive monolayers as described above. This modification of the conventional infectious center assay will allow infected cells 12 h to complete the lytic cycle and form infectious particles in vitro. This will ensure that we are not erroneously scoring lytically infected cells as latently infected because they are in an early stage of lytic infection and fail to form plaques.

Cell purification

Lung B and stromal cells were purified on a FACSVantage SE/Diva sorter (BD Biosciences) as described elsewhere (16). Briefly, pooled lung cell suspensions from four mice obtained as described above were stained with Abs against CD11c (HL3), CD11b (M1/70), CD5 (53-7.3), and CD19 (1D3) (BD Pharmingen). B cells were sorted as CD19+ and negative for the other markers with a mean purity of 90%. A population of stromal cells (97% purity) was sorted as negative for all of the markers used, therefore lacking macrophages, granulocytes, NK cells, T and B lymphocytes, and dendritic cells.

Gardella gel electrophoresis

The resolution of episomal and linear {gamma}HV68 genomes in lung B cells purified as described above was done by Gardella gel analysis (18, 19). The lysis and separating gels were prepared as described previously (19). Purified B cells were resuspended in loading buffer containing 20% Ficoll (Sigma-Aldrich) and 0.01% bromphenol blue and then loaded onto the gels. The sample was overlaid with lysis buffer containing 5% Ficoll, 1% SDS, and 1 mg/ml self-digested Pronase (Calbiochem). The gels were run at 4°C at 40 V for 3 h and then at 160 V for 16 h. The gels were then sliced at 0.5-cm intervals, the agarose was digested, and the DNA was extracted using {beta} agarase (Promega) and ethanol precipitation following the manufacturer’s instructions. The presence of {gamma}HV68 DNA in the samples was determined by PCR in a 25-µl reaction containing primers (6.25 µmol each) specific for {gamma}HV68 (5'-GATGGAAACAGAAAACGAGCCC-3' and 5'-TCGCTTGTTTCTGGGGAGGTTT-3', product 425 bp), 1 U of TaKaRa Ex Taq (Takara Biomedicals), 2.5 µl of 10x Ex Taq buffer (Takara Biomedicals), and 3 µl of dNTP mixture (Takara Biomedicals). Amplification was for 45 cycles (94°C, 60 s; 67°C, 60 s; 72°C, 30 s), followed by a 7-min extension at 72°C. The {gamma}HV68-containing B cell line S11, which has been shown to harbor both episomal and linear {gamma}HV68 DNA (20), was used as a control for the Gardella gel analysis.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Latently infected cells constitute a large fraction of the infected cell pool during acute primary infection

Intranasal infection with {gamma}HV68 results in a lytic infection in the lung, which is cleared by the host immune system. Despite this, the virus sneaks through, and latency is established. The numbers of latently infected cells peaks at day 14 in the spleen and latency is localized primarily in activated, germinal center B cells, as well as macrophages and dendritic cells. Over the long term, the virus persists in a latent state predominantly in resting memory B cells in the spleen, respiratory tract, and other anatomical sites (6, 16, 20). We had previously shown that there were high frequencies of latently infected B cells in the lung at 14 days after infection, but it was not clear whether latency was initiated in the spleen and latently infected cells migrated back to the lung or whether lung B cells were latently infected in situ. To determine when latency in the lung was first established, we monitored lytic and latent virus in the lung at various time points after intranasal infection. As expected, the titer of lytic (infectious) viral particles in lung tissue homogenates as determined by a standard plaque assay peaked between days 5 and 9 and was cleared by day 14 (Fig. 1a). However, determination of the number of cells harboring viral genome using a limiting dilution-nested PCR assay showed a different pattern, in that the number of cells carrying {gamma}-herpesvirus DNA remained stable even after infectious cell-free virus could no longer be detected (Fig. 1b). In addition, the number of infected cells was 10- to 100-fold higher than the absolute number of plaques produced by lytic virus. These data suggested that many of the cells harboring viral genome in the lung during the first 2 wk of infection are latently infected, consistent with the possibility that lytic and latent infection coexist in the respiratory tract from the beginning of the infection.



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 1. {gamma}-Herpesvirus latently infected cells constitute a large fraction of the cellular reservoir during primary lung infection. a, Preformed virus peaks between days 7 and 9 and is not detected by day 14. Free infectious virus was determined by plaque assay of lung homogenates. b, The number of cells carrying {gamma}HV68 DNA remained stable 2 wk after infection. Cells harboring viral genome were determined by a limiting dilution-nested PCR assay. c, The total number of infected cells remained stable at day 14. An infectious center assay was used to identify infected cells based on the ability of the infected cells to reactivate in vitro and to form plaques on a susceptible monolayer. d, The cells harboring latent virus constitute a large fraction of the infected cells during primary respiratory infection. The number of lytically infected cells ({circ}) was determined by analysis of a suspension of killed lung cells in an infectious center assay The number of latently infected cells (•) was determined by subtracting the number of lytically infected cells from the absolute number of infected cells. Each symbol represents analysis of an individual animal (n = 3–6).

 
To quantitate productively infected cells, we used an infective center assay (16). This assay detects virally infected cells by their ability to form plaques on a susceptible monolayer following in vitro incubation. Lytically infected cells form plaques directly, whereas latently infected cells only form plaques in vitro following spontaneous reactivation. Although the reactivation assay (Fig. 1c) is less sensitive than the PCR assay (Fig. 1b), the total numbers of {gamma}HV68-infected cells detected by both assays showed a similar pattern of infection, in that the infected cells remained high at a time when lytic virus was being cleared. Since reactivation of latent virus requires the presence of live cells, cells carrying latent virus are determined by subtracting the plaques determined by analysis of killed cells (lytic) from the total plaques (lytic plus latent). The data (Fig. 1d) show that most of the {gamma}-herpesvirus-reactivating cells scored as latently infected in this assay.

Although the data suggest that a high proportion of the cells harbor latent virus, it is possible that the in vitro reactivation assay overestimated the number of latently infected cells. In vivo infections are nonsynchronous and thus any {gamma}HV68-infected cell committed to viral replication but not yet producing infectious viral particles will score as latently infected in an infectious center assay. Therefore, to assess the contribution of cells in the early stages of lytic replication to the latent pool, we modified the infectious center assay to allow infected cells to complete their lytic cycle in vitro. Thus, a lung cell suspension from acutely infected mice was sampled at different intervals (0, 8, and 12 h) during in vitro incubation and assayed in the infectious center assay. If the cells assessed by this assay to be latent were really in the early stages of lytic infection, the apparent latent titers would be expected to fall with increasing in vitro incubation, and the lytic titers would increase. However, the data show that substantial numbers of latently infected cells were detected at all three time points analyzed (Fig. 2). Altogether, our results support the idea that viral latency constitutes a large component of the acute primary {gamma}HV68 infection.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 2. The number of {gamma}HV68 latently infected cells in the lung does not decrease after in vitro incubation. A single-cell suspension from acutely infected lungs was incubated at 37°C to allow lytically infected cells to complete the viral replication cycle. Cells were sampled at 0, 8, and 12 h and processed as described in Materials and Methods. The number of lytically ({square}) and latently ({blacksquare}) infected cells was determined using an infectious center assay. Lung cells were pooled from six lungs at day 7 after infection. Error bars represent SD.

 
Latency is established in lung B cells immediately after respiratory infection

The previous data indicate the presence of latently infected cells in the lung using viral quantification assays. We also used a molecular approach to identify latent and replicative forms of viral DNA early during lytic infection. Latent {gamma}-herpesvirus DNA is episomal (covalently, closed circular) whereas lytic, replicating virus is in a linear conformation (20, 21). Gardella gels differentiate latent episomal from lytic linear viral DNA on the basis of electrophoretic mobility (18). Therefore, to demonstrate the presence of latent virus at early time points, we determined the conformational state of the viral DNA harbored in sort-purified lung B cells at day 3 following intranasal infection by Gardella gel analysis. The migration properties of linear and circular DNA were confirmed by analysis of DNA from S11 cells, a B cell line known to harbor both lytic and latent virus (20, 22). The data show that B cells isolated from the lung 3 days after {gamma}HV68 infection harbor both circular and linear viral genomes (Fig. 3a). Episomal DNA indicates the presence of latent virus. The presence of both circular and linear DNA in the purified B cells is consistent with the pattern of DNA observed following in vitro infection of B cells with EBV (23). Cells initially contained linear genomes, some of which migrated to the nucleus. Circular DNA in that synchronous infection was first detected by 20 h after infection, but only a small amount of the total EBV DNA within infected cells assumed a circular conformation. The possibility that the coexistence of circular and linear {gamma}HV68 DNA in lung B cells in our experiments reflects the presence of replicative intermediates of the lytic infection which occurs by a rolling circle mechanism, rather than latent virus, is unlikely, as the replicative {theta} form of the virus would be a very minor component of virus in a cell that is undergoing lytic replication. The failure to detect circular DNA in cells undergoing lytic infection was confirmed by Gardella gel analysis of DNA from lytically infected 3T3 cells (Fig. 3). The Gardella gel analysis, taken along with the viral assays, strongly supports the interpretation that latency is established early during the lytic infection.



View larger version (59K):
[in this window]
[in a new window]
  		FIGURE 3. {gamma}HV68 establishes latency in lung B cells very early following respiratory infection. a, Lung B cells contain both latent (episomal) and lytic (linear) virus at day 3 after infection. Gardella gel analysis of DNA from S11 cells, a {gamma}HV68 latently infected B cell tumor line that has been shown to contain both episomal and linear genomes (20 ) (top panel), acutely infected 3T3 fibroblasts (middle panel) and of FACS-sorted CD19+ B cells from lungs 3 days after {gamma}HV68 infection (bottom panel). The gel photograph shows PCR for viral DNA of sequential individual gel slices, starting from the top of the gel (left to right). The slower migrating episomal DNA indicates latent viral genome and the faster migrating linear DNA represents lytic viral genome. b, {gamma}HV68 can be detected both in stromal and B cells as early as day 1 after respiratory infection. The numbers of FACS-purified lung stromal cells (CD19–CD11c–CD11b–CD5–) ({circ}) and lung CD19+ B cells (•) harboring viral genome at indicated times after intranasal infection were determined by limiting dilution-nested PCR.

 
Next, we kinetically analyzed {gamma}HV68 infection in FACS-purified lung B lymphocytes and stromal cells (nonlymphoid and nonmyeloid cells). The data show that the virus could be detected in both cell subsets as early as day 1 after infection (Fig. 3b). These results, demonstrating that B lymphocytes harbor {gamma}HV68 almost immediately after respiratory infection and that latency is established as early as 3 days after infection, support the hypothesis that viral infection of B lymphocytes is a concurrent event with the ongoing lytic infection of the mucosal epithelium. The continued high levels of virus in the stromal cells after clearance of infectious virus at day 11 (Fig. 1a) may be partly attributable to latency in the epithelial cells contained within the stromal cells (20) or attributable to the persistence of viral nucleic acid after the elimination of virally infected cells, as described previously (24, 25, 26).

{gamma}-Herpesvirus latency can be established in the absence of viral replication

The finding that {gamma}-herpesvirus latency is established in lung B cells very early after mucosal infection prompted us to assess the relationship between lytic and latent infection. Mice were infected with {gamma}HV68 and then, 3 days later, were treated daily with cidofovir, which has been shown to halt ongoing {gamma}HV68 replication in vitro and vivo (14, 15, 27, 28). By day 3, latent infection has already been initiated in lung (Fig. 3). Thus, if the latency pool expands after the initiation of the cidofovir treatment, it would indicate that this process is independent of viral replication. Cidofovir-treated and control mice were then analyzed on day 14, the peak of viral latency in the spleen (29). The data show that the number of latently infected cells in both the lung and spleen of cidofovir-treated mice are not significantly different from the control mice (Fig. 4). Successful inhibition of {gamma}HV68 replication in the lungs was confirmed by analysis of lytic virus in the drug-treated mice on day 7, at the peak of acute infection. The cidofovir-treated animals showed a 10,000-fold reduction in the number of infectious viral particles per lung compared with nontreated controls (Fig. 4c). These results suggest that once the primary infection is initiated, the establishment of latency can proceed independently of the lytic infection by cellular proliferation of the latently infected cells.



View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 4. Inhibition of viral replication once early latency has been established has no impact on the latent viral load. Mice were i.p. inoculated daily with cidofovir ({circ}) or PBS (•) starting 3 days after {gamma}HV68 infection. Fourteen days after infection, latent viral load was assayed in lung (a) and spleen (b). Each symbol represents analysis of an individual animal (n = 4). The lack of significant differences was determined by Student’s t test, lung p = 0.17, spleen p = 0.31. c, Plaque assay showing the number of infectious viral particles in cidofovir-treated and nontreated mice at day 7 after infection (day 4 of cidofovir treatment) and at the initiation of the treatment. Each bar represents the mean value of four to five individual mice analyzed, and error bars represent SD.

 
To formally determine whether the establishment of latency absolutely depends on lytic viral replication, we infected mice using a replication-deficient {gamma}HV68 virus ({gamma}HV68 ORF31STOP). This virus was generated by inserting a stop codon to disrupt expression of open reading frame 31 (13). Open reading frame 31 is conserved among the {beta}- and {gamma}-herpesviruses, does not have a mammalian homologue, and is of unknown function. Importantly, disruption of ORF31 expression renders the virus completely incapable of in vitro replication and the virus can only be grown by trans rescue with either {gamma}HV68 or KSHV ORF31 (13). We inoculated mice both intranasally and i.p. with {gamma}HV68 ORF31STOP and wild-type virus and monitored splenic latency 14 and 30 days later (Fig. 5). After i.p. inoculation of the replication-deficient virus, latency was established in spleen cells, albeit at lower levels than after inoculation with wild-type {gamma}HV68. At 14 days after infection, the normal peak of latency, the reciprocal frequency of cells harboring viral genome after i.p. infection with ORF31STOP was 1 in 5800 cells compared with the frequency after i.p. infection with the wild-type virus of 1 in 177 cells. As expected, the latency frequency of wild-type virus declined to 1 in 1897 at 30 days after infection, whereas the frequency of cells latently infected with the replication-deficient virus remained relatively constant. The recombinant virus was constructed with a BamHI restriction site to differentiate the actual transgenic virus from wild-type virus (13). Restriction enzyme analysis of PCR-amplified viral DNA extracted from spleen cells isolated from mice infected i.p. with {gamma}HV68 ORF31STOP confirm that the virus harbored by the latently infected cells at both 14 and 30 days after i. p. infection is the replication-deficient mutant virus (Fig. 5c). These data are the first conclusive demonstration that the establishment of {gamma}-herpesvirus latency in vivo is independent of lytic viral replication.



View larger version (44K):
[in this window]
[in a new window]
  		FIGURE 5. A replication-defective {gamma}-herpesvirus is capable of establishing splenic latency. The percentage of spleen cells harboring viral genome after intranasal ({circ}, {square}) and i.p. (•, {blacksquare}) infection with wild-type {gamma}HV68 ({circ}, • or {gamma}HV68 ORF31STOP ({square}, {blacksquare}) was assessed by limiting dilution assay (LDA)-PCR assay 14 days (a) and 30 days (b) after infection. BamHI restriction enzyme analysis of PCR-amplified {gamma}HV68 DNA from 14 days (c) and 30 days (d) after infection. Lane 1, Positive control, DNA extracted from BHK-21 cells transfected with 31STOP Bac plasmid. Lane 2, DNA extracted from spleens of mice intranasally infected with 400 PFU of wild-type {gamma}HV68. Lane 3, DNA extracted from spleens of mice i.p. infected with 7 x 105 PFU of ORF31STOP {gamma}HV68. Lane 4, DNA extracted from spleens of mice intranasally infected with ~3 x 105 PFU of ORF31STOP {gamma}HV68. Lane 5, DNA extracted from spleens of mice i.p. infected with 106 PFU of wild-type {gamma}HV68.

 
In contrast to the results with i.p. infection, intranasal inoculation with a comparable viral dose of {gamma}HV68 ORF31STOP was not capable of establishing latent infection at either 14 or 30 days after infection (Fig. 5). That the ability of a replication-defective virus to establish latency is dependent on the site of inoculation supports the possibility that although lytic replication is not required for the establishment of latency per se, it plays another as yet undefined essential role, such as facilitating viral access to its host target cells. Altogether, the data indicate that lytic viral replication is not a requirement for {gamma}-herpesvirus latency once the virus has penetrated the mucosal barrier and that latency can be disseminated by cellular proliferation.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In the current study, we have examined the early events following mucosal infection of mice with {gamma}HV68. The data show that latent infection can be established very early during the acute response and that B lymphocytes in the lung harbor latent virus as early as 3 days after infection. Remarkably, not only can latency proceed after inhibition of the lytic cycle early after infection, but latency can also be established in the complete absence of lytic replication following in vivo infection with a replication-deficient virus. On the basis of these data, we propose a model of {gamma}-herpesvirus infection (Fig. 6) in which lytically and latently infected cells coexist at the mucosal site of infection, and in which latently infected cells constitute a major component of the early infection at the entry site. These observations provide new insight into early {gamma}-herpesvirus infection and have important implications for understanding immune control of the virus and for developing prophylactic vaccination strategies.



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 6. Kinetics of {gamma}HV68 primary infection. a, Classic model of infection. Following intranasal inoculation, there is a sharp rise in lytic virus, which is cleared by host immune mechanisms. Latent virus is first detected at ~6 days after infection in the spleen and draining lymph nodes, peaks at approximately day 14, and declines to a low, stable level. b, New model of infection. Latent virus dominates the acute phase of infection and latently infected B cells are detectable in the lung as early as day 3 after infection. Latency can be established in the absence of lytic replication. Lytic virus in the lung is indicated by the dashed line (shaded peak), latent virus in the spleen is indicated by the solid line, and latent virus in the lung is indicated by the dotted line.

 
These studies enhance our understanding of the relationship between lytic and latent infection. A direct correlation between lytic virus and the latent load has been shown for CMV, a {beta}-herpesvirus (30), but not HSV, an {alpha}-herpesvirus (31). Recent data for {gamma}HV68 suggested that establishment of {gamma}-herpesvirus latency was similarly independent of the infectious dose beyond the level required to infect 100% of the mice (32). Relative independence of latency on lytic load was also demonstrated by studies of a mutant {gamma}HV68, lacking thymidine kinase. Despite severe attenuation of lytic cycle replication in vivo, the virus still established latency (33). The current study provides the first demonstration that {gamma}-herpesvirus latency can be established in vivo after infection with a completely replication-deficient virus.

The ability to establish latency in the absence of lytic infection has relevance for understanding the mechanisms by which latency is disseminated throughout the host. A common characteristic of the {gamma}-herpesviruses is that they exploit the host B lymphocyte life cycle to establish and maintain long-term latency (3, 4, 5, 6, 7, 8). The finding that {gamma}-herpesvirus latency is established in lung B cells as early as 3 days after respiratory infection reinforce the central role of the B cell not only in the later phase of infection, but early in the initial infection. Following the early infection of B cells, amplification of the infected pool can apparently occur by cellular proliferation rather than lytic viral spread and subsequent latent infection, thus avoiding immune detection. The observation that establishment of latency is independent of lytic virus suggests that the spread of latency is accomplished by cellular proliferation. That latency can be established by migration and proliferation of latently infected B cells has been reported (20). More recently, analysis of a gp150-deficient virus led to the conclusion that in vivo host colonization is independent of virion release, suggesting that cell-cell virus spread and cellular proliferation of latently infected cells are essential for the establishment of latency (34). Moreover, our results blocking viral replication with the drug cidofovir also demonstrate that once latent infection has been initiated, the lack of viral replication does not impact the dissemination of latency. In agreement with this result, it was previously shown that establishment of latency was delayed, but not prevented, after pretreatment with acyclovir (35).

Although B cells are the major target of {gamma}-herpesvirus latency (9), other cell subsets have been identified as {gamma}HV68 reservoirs in various anatomical sites, including the lung (16, 20, 36, 37). In the current manuscript, we have focused on early B cell latency. However, as part of a separate study, we have evidence to suggest that lung dendritic cells are also an early reservoir of latency (E. Flaño and M. A. Blackman, unpublished observations). In addition, the persistence of viral genome in lung stromal cells after the clearance of lytic virus in this report (Fig. 3b) raises the possibility that latency is established in lung epithelial cells within 2 wk of intranasal infection. We have not yet examined macrophages as an early reservoir of latency. Taken together, the data suggest that latency is established early in multiple cellular reservoirs in the lung. An important issue for future investigation is the contribution of each of these early reservoirs to the spread and maintenance of latency in the host.

If latency can be effectively established after infection with a replication-deficient virus, is the only role for lytic replication to allow the virus to be efficiently transmitted to another host? The finding that the replication-deficient virus only established latency after i.p. infection indicates that lytic replication also plays an essential role in the establishment of latency when the epithelial barrier is intact. One likely possibility is that viral replication is essential for the virus to cross the epithelial barrier and gain access to the leukocyte pool. An alternative possibility is that lytic replication is necessary to induce an inflammatory response in the lung, so that a sufficient pool of (activated?) B cells is available in situ for efficient latent infection. Further experimentation is necessary to distinguish these possibilities.

The ability to establish latent infection in vivo in the absence of lytic replication also provides insight into mechanisms of immune evasion. Our data raise the possibility that the lytic infection may play an important role in the establishment of latency by eliciting strong immunity and thus diverting the host immune response away from the latent infection. This possibility is supported by the observation that the early immune response to EBV is largely directed toward lytic viral epitopes, and T cells specific for latent epitopes are infrequent or absent during infectious mononucleosis (38, 39). In the {gamma}HV68 system, T cells responding to the only known latent epitope are not detectable in the lung, mediastinal lymph node, or spleen until 19 days after infection (40). Herpesviruses establish a delicate equilibrium with the host: they depend on immune control for their host’s survival (and hence their own), yet must impair immunity to avoid eradication (41). The demonstration of an early latent infection in the apparent absence of a T cell response directed at latent Ags supports the possibility that {gamma}-herpesviruses accomplish this equilibrium in part by directing most of the immune resources toward controlling an ongoing lytic infection while allowing the establishment of lifelong latency. Viruses have evolved a number of strategies to evade immune responses (42). In this sense, {gamma}-herpesviruses are highly adapted to counterattack host control interfering with Ag presentation, cell cycle and survival as well as chemokine and cytokine activity among other strategies (43, 44). In addition, they shut down viral genes and establish lifelong latency, exploiting host mechanisms of cellular homeostasis (9, 45). In this study, we propose another immune evasion mechanism, that the strongly immunogenic lytic phase of the infection serves to distract the immune system and allows the latent virus to establish a foothold. Confirmation of this hypothesis awaits detailed characterization of the immune response elicited by the replication-deficient ORF31STOP virus.

Our findings have important implications for the design of vaccine strategies against {gamma}-herpesviruses. {gamma}HV68 provides an experimental model in which fundamental principles of vaccination for the {gamma}-herpesviruses can be tested. A common approach has been to target early lytic replication based on the general notion that the temporal lag between the lytic and latent stages of infection would allow successful interference with the establishment of latency. Early results with vaccination protocols that targeted the lytic cycle were shown to reduce the overall viral load in the lung and the early peak of latency in the spleen, but had no impact on long-term latency (46, 47, 48, 49). The failure of this approach can be explained by our current finding that latency is established early after infection at the mucosal site of entry and is not dependent on sustained viral replication. Thus, effective {gamma}-herpesvirus vaccination strategies must target not only infectious virus, but also lytically and latently infected cells in the oral mucosa and respiratory tract. Importantly, the ability of a replication-deficient virus to establish latency after i.p. inoculation points out the risks associated with attenuated vaccine strains and emphasizes the importance of epitope-based vaccines. In conclusion, analysis of the early events in {gamma}HV68 infection in an in vivo model has enhanced our understanding of mechanisms for the establishment and dissemination of latency in an immunocompetent host. The {gamma}HV68 system provides a valuable in vivo experimental model for testing "proof of principal" vaccination strategies.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Acknowledgments
 
We thank Simon Monard for assistance with the FACS sorting and Dr. In-Jeong Kim for discussion and critical analysis of this manuscript.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grants AI42927 and AI51602 and by the Trudeau Institute (to M.A.B.) and National Institutes of Health Grants CA91791, DE14153, and DE15752 and the Stop Cancer Foundation (to R. S.). Back

2 Current address: Center for Vaccines and Immunity, Columbus Children’s Research Institute, Columbus, OH 43205. Back

3 Address correspondence and reprint requests to Dr. Marcia A. Blackman, Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983. E-mail address: mblackman{at}trudeauinstitute.org. Back

4 Abbreviations used in this paper: KSHV, Kaposi’s sarcoma-associated herpesvirus; MHV-68, murine {gamma}-herpesvirus 68; {gamma}HV68, {gamma}-herpesvirus 68. Back

Received for publication October 12, 2004. Accepted for publication February 10, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Virgin, H. W., P. Latreille, P. Wamsley, K. Hallsworth, K. E. Weck, A. J. Dal Canto, S. H. Speck. 1997. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 71:5894.[Abstract]
  2. Blackman, M. A., E. Flaño. 2002. Persistent {gamma}-herpesvirus infections: what can we learn from an experimental mouse model?. J. Exp. Med. 195:F29.
  3. Moore, P. S., Y. Chang. 2003. Kaposi’s sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?. Annu. Rev. Microbiol. 57:609.[Medline]
  4. Thorley-Lawson, D. A., G. J. Babcock. 1999. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci. 65:1433.[Medline]
  5. Rickinson, A. B., P. J. L. Lane. 2000. Epstein-Barr virus: co-opting B-cell memory and migration. Curr. Biol. 10:R120.[Medline]
  6. Flaño, E., I. J. Kim, D. L. Woodland, M. A. Blackman. 2002. {gamma}-Herpesvirus latency is preferentially maintained in splenic germinal center and memory B cells. J. Exp. Med. 196:1363.[Abstract/Free Full Text]
  7. Kim, I. J., E. Flaño, D. L. Woodland, F. E. Lund, T. D. Randall, M. A. Blackman. 2003. Maintenance of long term {gamma}-herpesvirus B cell latency is dependent on CD40-mediated development of memory B cells. J. Immunol. 171:886.[Abstract/Free Full Text]
  8. Willer, D. O., S. H. Speck. 2003. Long-term latent murine gammaherpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells in vivo. J. Virol. 77:8310.[Abstract/Free Full Text]
  9. Rickinson, A. B., E. Kieff. 1996. Epstein-Barr virus. D. M. Knipe, and B. N. Fields, and P. M. Howley, eds. Fields Virology 2397. Lippincott Williams & Wilkins, Philadelphia.
  10. Cohen, J. I.. 2000. Epstein-Barr virus infection. N. Engl. J. Med. 343:481.[Free Full Text]
  11. Tierney, R. J., N. Steven, L. S. Young, A. B. Rickinson. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374.[Abstract/Free Full Text]
  12. Doherty, P. C., J. P. Christensen, G. T. Belz, P. G. Stevenson, M. Y. Sangster. 2001. Dissecting the host response to a {gamma}-herpesvirus. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356:581.[Medline]
  13. Jia, Q., T. T. Wu, H. I. Liao, V. Chernishof, R. Sun. 2004. Murine gammaherpesvirus 68 open reading frame 31 is required for viral replication. J. Virol. 78:6610.[Abstract/Free Full Text]
  14. Smee, D. F., R. A. Burger, R. P. Warren, K. W. Bailey, R. W. Sidwell. 1997. An immunosuppressed mouse model of lethal murine gammaherpesvirus 68 infection for studying potential treatment of Epstein-Barr virus infection in man. Antiviral Chem. Chemother. 8:573.
  15. Neyts, J., E. De Clercq. 1998. In vitro and in vivo inhibition of murine {gamma} herpesvirus 68 replication by selected antiviral agents. Antimicrob. Agents Chemother. 42:170.[Abstract/Free Full Text]
  16. Flaño, E., I. J. Kim, J. Moore, D. L. Woodland, M. A. Blackman. 2003. Differential {gamma}-herpesvirus distribution in distinct anatomical locations and cell subsets during persistent infection in mice. J. Immunol. 170:3828.[Abstract/Free Full Text]
  17. Virgin, H. W., R. M. Presti, X. Y. Li, C. Liu, S. H. Speck. 1999. Three distinct regions of the murine gammaherpesvirus 68 genome are transcriptionally active in latently infected mice. J. Virol. 73:2321.[Abstract/Free Full Text]
  18. Gardella, T., P. Medveczky, T. Sairenji, C. Mulder. 1984. Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. J. Virol. 50:248.[Abstract/Free Full Text]
  19. Decker, L. L., G. J. Babcock, D. A. Thorley-Lawson. 2001. Detection and discrimination of latent and replicative herpesvirus infection at the single cell level in vivo. Methods Mol. Biol. 174:111.[Medline]
  20. Stewart, J. P., E. J. Usherwood, A. Ross, H. Dyson, T. Nash. 1998. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J. Exp. Med. 187:1941.[Abstract/Free Full Text]
  21. Decker, L. L., L. D. Klaman, D. A. Thorley-Lawson. 1996. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J. Virol. 70:3286.[Abstract]
  22. Usherwood, E. J., J. P. Stewart, A. A. Nash. 1996. Characterization of tumor cell lines derived from murine gammaherpesvirus-68-infected mice. J. Virol. 70:6516.[Abstract]
  23. Hurley, E. A., D. A. Thorley-Lawson. 1988. B cell activation and the establishment of Epstein-Barr virus latency. J. Exp. Med. 168:2059.[Abstract/Free Full Text]
  24. Hawke, S., P. G. Stevenson, S. Freeman, C. R. Bangham. 1998. Long-term persistence of activated cytotoxic T lymphocytes after viral infection of the central nervous system. J. Exp. Med. 187:1575.[Abstract/Free Full Text]
  25. Selvakumar, R., A. Schmitt, T. Iftner, R. Ahmed, F. O. Wettstein. 1997. Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression. J. Virol. 71:5540.[Abstract]
  26. Stevenson, P. G., J. S. May, X. G. Smith, S. Marques, H. Adler, U. H. Koszinowski, J. P. Simas, S. Efstathiou. 2002. K3-mediated evasion of CD8+ T cells aids amplification of a latent {gamma}-herpesvirus. Nat. Immunol. 3:733.[Medline]
  27. Gangappa, S., S. B. Kapadia, S. H. Speck, H. W. Virgin. 2002. Antibody to a lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-deficient mice. J. Virol. 76:11460.[Abstract/Free Full Text]
  28. Dal Canto, A. J., H. W. Virgin, S. H. Speck. 2000. Ongoing viral replication is required for gammaherpesvirus 68-induced vascular damage. J. Virol. 74:11304.[Abstract/Free Full Text]
  29. Cardin, R. D., J. W. Brooks, S. R. Sarawar, P. C. Doherty. 1996. Progressive loss of CD8+ T cell-mediated control of a {gamma}-herpesvirus in the absence of CD4+ T cells. J. Exp. Med. 184:863.[Abstract/Free Full Text]
  30. Reddehase, M. J., M. Balthesen, M. Rapp, S. Jonjic, I. Pavic, U. H. Koszinowski. 1994. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J. Exp. Med. 179:185.[Abstract/Free Full Text]
  31. Halford, W. P., P. A. Schaffer. 2000. Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants to establish wild-type levels of latency in vivo. J. Virol. 74:5957.[Abstract/Free Full Text]
  32. Tibbetts, S. A., J. Loh, V. Van Berkel, J. S. McClellan, M. A. Jacoby, S. B. Kapadia, S. H. Speck, H. W. Virgin. 2003. Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection. J. Virol. 77:7696.[Abstract/Free Full Text]
  33. Coleman, H. M., B. D. de Lima, V. Morton, P. G. Stevenson. 2003. Murine gammaherpesvirus 68 lacking thymidine kinase shows severe attenuation of lytic cycle replication in vivo but still establishes latency. J. Virol. 77:2410.[Abstract/Free Full Text]
  34. de Lima, B. D., J. S. May, P. G. Stevenson. 2004. Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J. Virol. 78:5103.[Abstract/Free Full Text]
  35. Sunil-Chandra, N. P., S. Efstathiou, A. A. Nash. 1994. The effect of acyclovir on the acute and latent murine gammaherpesvirus-68 infection of mice. Antiviral Chem. Chemother. 5:290.
  36. Weck, K. E., S. S. Kim, H. W. Virgin, S. H. Speck. 1999. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. J. Virol. 73:3273.[Abstract/Free Full Text]
  37. Flaño, E., S. M. Husain, J. T. Sample, D. L. Woodland, M. A. Blackman. 2000. Latent murine {gamma}-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J. Immunol. 165:1074.[Abstract/Free Full Text]
  38. Rickinson, A. B., M. F. Callan, N. E. Annels. 2000. T-cell memory: lessons from Epstein-Barr virus infection in man. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 355:391.[Medline]
  39. Hislop, A. D., N. E. Annels, N. H. Gudgeon, A. M. Leese, A. B. Rickinson. 2002. Epitope-specific evolution of human CD8+ T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195:893.[Abstract/Free Full Text]
  40. Obar, J. J., S. G. Crist, D. C. Gondek, E. J. Usherwood. 2004. Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection. J. Immunol. 172:1213.[Abstract/Free Full Text]
  41. Yewdell, J. W., A. B. Hill. 2002. Viral interference with antigen presentation. Nat. Immunol. 3:1019.[Medline]
  42. Tortorella, D., B. E. Gewurz, M. H. Furman, D. J. Schust, H. L. Ploegh. 2000. Viral subversion of the immune system. Annu. Rev. Immunol. 18:861.[Medline]
  43. Alcami, A., U. H. Koszinowski. 2000. Viral mechanisms of immune evasion. Trends Microbiol. 8:410.[Medline]
  44. Murphy, P. M.. 2001. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat. Immunol. 2:116.[Medline]
  45. Kieff, E.. 1996. Epstein-Barr virus and its replication. D. M. K. B. N. Fields, and P. M. Howley, eds. Fields Virology 2343. Lippincott Williams & Wilkins, Philadelphia.
  46. Liu, L., E. J. Usherwood, M. A. Blackman, D. L. Woodland. 1999. T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice. J. Virol. 73:9849.[Abstract/Free Full Text]
  47. Stevenson, P. G., G. T. Belz, M. R. Castrucci, J. D. Altman, P. C. Doherty. 1999. A {gamma}-herpesvirus sneaks through a CD8+ T cell response primed to a lytic-phase epitope. Proc. Natl. Acad. Sci. USA 96:9281.[Abstract/Free Full Text]
  48. Stewart, J. P., N. Micali, E. J. Usherwood, L. Bonina, A. A. Nash. 1999. Murine {gamma}-herpesvirus 68 glycoprotein 150 protects against virus- induced mononucleosis: a model system for {gamma}-herpesvirus vaccination. Vaccine 17:152.[Medline]
  49. Woodland, D. L., E. J. Usherwood, L. Liu, E. Flaño, I. J. Kim, M. A. Blackman. 2001. Vaccination against murine {gamma}-herpesvirus infection. Viral Immunol. 14:217.[Medline]



This article has been cited by other articles:


Home page
 J. Virol.Home page
H. Li, K. Ikuta, J. W. Sixbey, and S. A. Tibbetts
A Replication-Defective Gammaherpesvirus Efficiently Establishes Long-Term Latency in Macrophages but Not in B Cells In Vivo
J. Virol., September 1, 2008; 82(17): 8500 - 8508.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Kayhan, E. J. Yager, K. Lanzer, T. Cookenham, Q. Jia, T.-T. Wu, D. L. Woodland, R. Sun, and M. A. Blackman
A Replication-Deficient Murine {gamma}-Herpesvirus Blocked in Late Viral Gene Expression Can Establish Latency and Elicit Protective Cellular Immunity
J. Immunol., December 15, 2007; 179(12): 8392 - 8402.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I.-J. Kim, C. E. Burkum, T. Cookenham, P. L. Schwartzberg, D. L. Woodland, and M. A. Blackman
Perturbation of B Cell Activation in SLAM-Associated Protein-Deficient Mice Is Associated with Changes in Gammaherpesvirus Latency Reservoirs
J. Immunol., February 1, 2007; 178(3): 1692 - 1701.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. W. Upton and S. H. Speck
Evidence for CDK-Dependent and CDK-Independent Functions of the Murine Gammaherpesvirus 68 v-Cyclin
J. Virol., December 15, 2006; 80(24): 11946 - 11959.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. M. Moser, M. L. Farrell, L. T. Krug, J. W. Upton, and S. H. Speck
A Gammaherpesvirus 68 Gene 50 Null Mutant Establishes Long-Term Latency in the Lung but Fails To Vaccinate against a Wild-Type Virus Challenge
J. Virol., February 1, 2006; 80(3): 1592 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. C. Kemball, E. D. H. Lee, E. Szomolanyi-Tsuda, T. C. Pearson, C. P. Larsen, and A. E. Lukacher
Costimulation Requirements for Antiviral CD8+ T Cells Differ for Acute and Persistent Phases of Polyoma Virus Infection
J. Immunol., February 1, 2006; 176(3): 1814 - 1824.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. S. Barton, M. L. Lutzke, R. Rochford, and H. W. Virgin IV
Alpha/Beta Interferons Regulate Murine Gammaherpesvirus Latent Gene Expression and Reactivation from Latency
J. Virol., November 15, 2005; 79(22): 14149 - 14160.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Flano, B. Kayhan, D. L. Woodland, and M. A. Blackman
Infection of Dendritic Cells by a {gamma}2-Herpesvirus Induces Functional Modulation
J. Immunol., September 1, 2005; 175(5): 3225 - 3234.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow